These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31599396)

  • 21. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA
    Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Sun X; Xu S; Li Y; Lv X; Wei M; He M
    Expert Rev Clin Pharmacol; 2023 Mar; 16(3):245-256. PubMed ID: 36908219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
    Chen J; Wu X; Wang H; Lian X; Li B; Zhan X
    Curr Comput Aided Drug Des; 2024; 20(6):736-751. PubMed ID: 37691198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis.
    Huang Y; He H; Liang L; Zhang Y; Peng K; Wang Y; Wu J; Long X; Kairemo K; Goldberg H; Mendez LC; Gu D
    Chin Clin Oncol; 2024 Aug; 13(4):64. PubMed ID: 39238347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
    Zhou JX; Feng LJ; Zhang X
    Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.
    Stemmer A; Shafran I; Stemmer SM; Tsoref D
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33081005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP Inhibitors in Ovarian Cancer: A Review.
    O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
    Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer.
    Yuan H; Xiu L; Li N; Li Y; Wu L; Yao H
    J Gynecol Oncol; 2024 Jul; 35(4):e51. PubMed ID: 38246184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
    Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR
    Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Kunwor R; Silver DP; Abu-Khalaf M
    Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):186-196. PubMed ID: 37023220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis.
    Dai MF; Wang X; Xin WX; Kong SS; Xu WB; Ding HY; Fang L
    Expert Rev Anticancer Ther; 2024 Jul; 24(7):613-622. PubMed ID: 38761169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
    Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy.
    Cancanelli L; Mengato D; Di Spazio L; Rivano M; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):32-35. PubMed ID: 34779394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
    Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
    Zhang M; Yu X; Wang J; Li Y; Cao L
    J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    Xu Y; Ding L; Tian Y; Bi M; Han N; Wang L
    Front Oncol; 2020; 10():573801. PubMed ID: 33692936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.